Related Experiment Videos
Non-resectable slow-growing meningiomas treated by hydroxyurea.
David Loven1, Ruth Hardoff, Zvi Bar Sever
1Institute of Oncology, Ha'Emek Medical Center, Afula, Israel. loven_da@clalit.org.il
Journal of Neuro-Oncology
|April 10, 2004
Summary
Hydroxyurea did not prove effective for treating recurrent, non-resectable meningiomas. The chemotherapy agent failed to achieve response or halt disease progression in patients with slow-growing meningiomas.
Area of Science:
- Neuro-oncology
- Medical oncology
Background:
- Meningiomas are tumors arising from the meninges.
- Recurrent and non-resectable slow-growing meningiomas present treatment challenges.
Purpose of the Study:
- To evaluate the efficacy of hydroxyurea in treating recurrent and non-resectable slow-growing meningiomas.
Main Methods:
- A 2-year continuous chemotherapy protocol using hydroxyurea (20 mg/kg/day) was administered to twelve patients.
- Treatment response was assessed using clinical evaluation, computed tomography (CT), and 201-Thallium single photon emission CT.
Main Results:
- One patient demonstrated minimal response with clinical stabilization via CT.
- Nine patients experienced disease progression, with a median time to progression of 13 months.
- Two patients discontinued the study early due to severe hematological toxicity.
Conclusions:
- Hydroxyurea demonstrated no effectiveness in treating non-resectable slow-growing meningiomas.
- The drug failed to induce tumor response or prevent disease progression in this patient cohort.